Centene's Medicare Margin Unlock Is a Shrink Story, Not a Growth Story

Centene's stock has nearly doubled in four months, climbing from about $31 in the spring to roughly $65 today, within reach of its 52-week high. For a retail investor watching from the side, the natural worry is that the "margin recovery" story has already been paid for. Before deciding whether to chase, it is worth being precise about where that recovery actually comes from — because the answer is not what the headline question assumes.

The margin unlock does not run through growing Medicare Advantage

The conventional read is that Centene, a big government-funded managed care company, will fix its profits by growing its Medicare Advantage (MA) book. The evidence points the other way: its MA strategy is contraction, not expansion. Centene has been trimming the MA footprint for 2026 and plans further reductions in 2027, cutting members rather than chasing growth, and running employee buyouts as volumes shrink. Total Medicare membership (MA plus supplement) fell from about 1.11 million at the end of 2024 to 1.00 million a year later.

That is a sensible reaction to a structurally hostile rate environment. The Centers for Medicare & Medicaid Services (CMS) proposed only a 0.09% increase in Medicare Advantage payments for 2026 while tightening the risk-adjustment model that determines how much plans are paid for sicker members. Industry analysis from PwC estimates that more than 70% of MA plans are operating at breakeven or below, with the combined headwinds from risk-adjustment changes, Stars bonus recalibration, and pharmacy costs worth over $90 per member per month between 2023 and 2025. In plain terms, the federal government is squeezing what it pays into a business where most players already cannot earn a margin — so the "old story" of MA as a profit engine is stale on its own numbers.

Centene is not abandoning Medicare entirely. Its standalone prescription drug plans (PDP) grew 17% to 8.12 million members and run at a leaner cost structure than the rest of the company, so a smaller MA book does not mean giving up the growth that is actually working.

The 2026 beat is mostly an Affordable Care Act turnaround

The margin improvement that has driven Centene's rerating is showing up elsewhere. In the second quarter of 2026, the commercial medical loss ratio — the share of premium spent on medical care, where lower is better for profit — fell to 79.2% from 90.6% a year earlier. That swing came from the marketplace (ACA) business, which Centene expects to earn a 4.5% to 5% margin this year after a rough 2025, helped by premium hikes, easing medical trends, and a $180 million one-time favorability from a risk-adjustment settlement. Medicaid, still roughly half its membership, also ticked down to a 93.9% MLR from 94.9% as state payment rates caught up with member acuity.

The result is a company that has now raised full-year 2026 adjusted earnings-per-share guidance twice, to greater than $4.80, up from $2.08 in 2025. That is a real and public inflection. But the honest qualifier is that it does not restore Centene to its previous peak — adjusted EPS was $7.17 in 2024 before medical-cost spikes hit the sector — and a chunk of the improvement is one-time in nature.

What anchors the case

It is worth flagging how the proof is being carried here. For a health insurer, headline free cash flow is not a clean bridge the way it is for a manufacturer, because the reported figure is distorted by swings in claims reserves and pharmacy-rebate timing. So the anchor is adjusted EPS and the medical-loss-ratio path, not free cash flow. That is a legitimate basis, and it means slightly higher uncertainty than a pure FCF story would carry.

On that basis, the stock still looks reasonable rather than cheap. At roughly $65, Centene trades near 13.5 times this year's guided adjusted EPS of $4.80-plus. A managed care company recovering toward normalized earnings at that multiple is not obviously expensive, but it is also no longer the reset-price entry — the 90% run over the past four months happened while the estimates were being raised, and a buyer today is paying for the recovery rather than betting it merely shows up.

What would prove the margin recovery is real — or not

The bear case is specific and worth taking seriously. The ACA turnaround is partly funded by premium hikes and a non-recurring risk-adjustment settlement, and continued member losses as generous federal subsidies expired are expected as the year goes on. If the commercial margin fades once those one-time tailwinds roll off, the 2026 beat does not compound. The Medicare book carries its own test: management described the underlying MA trend as consistent with expectations, but with MA MLR at 89.5% and a 2027 rate round still to come, any renewal of utilization pressure would reassemble the old margin problem. And on Medicaid, pending federal cuts and new work requirements could remove roughly five million Americans from coverage in 2027, a real headwind to the biggest book.

The condition that would break the renewed story is simple: earnings that stop beating and margins that stop improving once the one-time favors fade. As long as adjusted EPS keeps being raised on the back of a leaner MA footprint and a healthier ACA book, the rerating has a foundation. The moment the MLR drifts back up, that foundation disappears.

Centene has answered the margin question in the most unfashionable way available: it is pruning the part of the business the government will not fund and leaning into the parts where it can reprice. The numbers are proving the pruning works. Whether the remaining upside at these levels is worth it depends on whether those margins hold once the easy, one-time gains are gone.